$RGNX News

REGENXBIO Announces First Patient Dosed In Phase IIb/III NAAVIGATE Clinical Trial Of Investigational Surabgene Lomparvovec In Diabetic Retinopathy Using Suprachoroidal Delivery; REGENXBIO To Receive $100M From Abbvie For This Milestone

HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $26 Price Target

REGENXBIO Completes Dosing In Its Confirmatory Study Of RGX-202 Gene Therapy For Duchenne Muscular Dystrophy

Baird Maintains Outperform on Regenxbio, Raises Price Target to $32

Leerink Partners Maintains Outperform on Regenxbio, Raises Price Target to $18

REGENXBIO Says FDA Path Opens for Hunter Syndrome Gene Therapy, Plans Quick FDA Resubmission for One-Time Rare Disease Treatment

Regenxbio: Duchenne Data Keeps Me Bullish, There's Less Room For Setbacks Now

'FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says' - WSJ

HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $26

REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Regenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results

B of A Securities Maintains Buy on Regenxbio, Lowers Price Target to $14

Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $12

REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript

REGENXBIO INC (NASDAQ:RGNX) Plunges 17% on Q1 Revenue Miss Despite Positive DMD Gene Therapy Trial Results

REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval

Regenxbio's Shares Topline And Interim Functional Data From Pivotal Phase 3 Portion Of Phase 1/2/3 Affinity Duchenne Trial Of RGX-202 For Duchenne Muscular Dystrophy, Meeting The Primary Endpoint With High Statistical Significance

Regenxbio Enters Settlement And Release Agreement With GlaxoSmithKline On March 18, 2026; To Pay $10.0M To GlaxoSmithKline For Alleged Underpayment Of Sublicense Fees; Settlement Agreement Includes Mutual Releases Of Past And Certain Future Claims; To Continue To Pay GSK Amounts Received From Sublicensees Pursuant To Existing Sublicense Agreements

REGENXBIO Inc. (RGNX) Presents at 2026 MDA Clinical & Scientific Conference - Slideshow

Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals